Ricin toxin's enzymatic subunit (RTA) has been subjected to intensive B cell epitope mapping studies using a combination of competition ELISAs, hydrogen exchange-mass spectrometry and X-ray crystallography. Those studies identified four spatially distinct clusters (I-IV) of toxin-neutralizing epitopes on the surface of RTA. Here we describe A9, a new single domain camelid antibody (V H H) that was proposed to recognize a novel epitope on RTA that straddles clusters I and III. The X-ray crystal structure of A9 bound to RTA (2.6 Å resolution) revealed extensive antibody contact with RTA's β-strand h (732 Å 2 buried surface area; BSA), along with limited engagement with α-helix D (90 Å 2 ) and α-helix C (138 Å 2 ). Collectively, these contacts explain the overlap between epitope clusters I and III, as identified by competition ELISA. However, considerable binding affinity, and, consequently, toxin-neutralizing activity of A9 is mediated by an unusual CDR2 containing five consecutive Gly residues that interact with α-helix B (82 Å 2 ), a known neutralizing hotspot on RTA. Removal of a single Gly residue from the penta-glycine stretch in CDR2 reduced A9's binding affinity by 10-fold and eliminated toxin-neutralizing activity. Computational modeling indicates that removal of a Gly from CDR2 does not perturb contact with RTA per se, but results in the loss of an intramolecular hydrogen bond network involved in stabilizing CDR2 in the unbound state. These results reveal a novel configuration of a CDR2 element involved in neutralizing ricin toxin.
Introduction
Ricin is a member of the type II ribosome-inactivating protein (RIP) family of plant toxins (Mantis, 2014; Schrot et al., 2015) . In its mature form, ricin is a 65 kDa glycoprotein consisting of two subunits, RTA and RTB, joined by a single disulfide bond (Katzin et al., 1991) . RTA is an RNA N-glycosidase (EC 3.2.2.22) that inactivates eukaryotic ribosomes through cleavage of a conserved ribosomal RNA element known as the sarcin-ricin loop (SRL) . RTB is a galactose/N-acetyl galactosamine-specific lectin that mediates ricin attachment and entry into mammalian cells, including lung epithelial cells and alveolar macrophages (Rutenber et al., 1987) . Following uptake, RTB facilitates the retrograde trafficking of ricin to the endoplasmic reticulum where RTA is liberated from RTB and then retrotranslocated into the cytosol via a Sec61-dependent pathway (Spooner and Lord, 2012) . Cell death occurs via apoptosis following ribosome inactivation (Tesh, 2012) .
Ricin is classified as a biothreat agent by the Centers for Diseases Control and Prevention (CDC) because of its capacity to induce multi-organ failure depending on the route of exposure. In nonhuman primates, ricin induces severe pulmonary inflammation with a marked influx of neutrophils, alveolar edema and hemorrhage that can lead to death of the animals within a 24-36 h period (Pincus et al., 2015; Roy et al., 2015) . However, the effects of ricin toxin can be partially, or possibly even completely, mitigated by antibodies directed against RTA (Colombatti et al., 1986 (Colombatti et al., , 1987 Maddaloni et al., 2004; O'Hara et al., 2010; O'Hara et al., 2012a; 2012b; Noy-Porat et al., 2016) . Evidence to support this claim comes from the fact that Rhesus macaques vaccinated intramuscularly with RiVax, an attenuated full length recombinant derivative of RTA adsorbed to aluminum salts, were protected against a 3-5 × LD 50 dose ricin challenge by aerosol . Similar results have been reported in mice (Smallshaw et al., 2007) . Passive and active vaccination strategies have demonstrated unequivocally that toxin-specific serum IgG antibodies are integral to the systemic and mucosal immune responses to ricin, although the specific B cell epitopes on RiVax that are associated with protective immunity have not been fully defined.
For the sake of vaccine development, we have argued that it is critical to define the antibody repertoire and B cell epitopes associated with protective immunity to ricin toxin . Towards this end, we used competition ELISAs, X-ray crystallography and hydrogen deuterium exchange-mass spectrometry (HX-MS) to localize epitopes on ricin recognized by dozens of monoclonal antibodies (mAbs) and camelid heavy chain-only antibody VH domains (V H Hs) (Rudolph et al., 2014 (Rudolph et al., , 2016 Rong et al., 2017; Toth et al., 2017; Vance et al., 2017) . Four immunodominant epitope clusters (I-IV) on RTA were identified when a panel of nine toxin-neutralizing mAbs was mapped by HX-MS (Fig. S1 ). Cluster I involved contact with RTA's β-strand h (residues 112-118) and α-helix B (residues 94-107), a protruding immunodominant secondary structure element previously known to be a target of potent toxin-neutralizing antibodies. Cluster II was divided into two subclusters, one involving α-helix A (residues 14-24) and α-helices F-G (residues , and the other encompassing β-strand d (residues 62-69) and parts of α-helices D-E (154-164) and the intervening loop. Cluster III encompassed α-helices C (residues 123-130) and G (residues 202-219) on the front side of RTA, while Cluster IV formed a diagonal sash from the front to back of RTA spanning β-strands b-d (residues 35-59). These results suggest that toxin-neutralizing epitopes are confined to very specific sectors on the surface of RTA. However, the picture is more complicated, as epitope analysis of a collection of 68 unique V H Hs (31 targeting RTA) resolved 11 different competition bins covering slightly more than 50% of the surface area of RTA . While the majority of epitopes were confined within clusters I-IV, a proportion of V H Hs displayed inter-cluster competition profiles, indicative of additional antibody binding sites on the surface of RTA.
The current study describes the molecular interactions between a new single domain camelid antibody A9 and RTA. This work advances our ongoing effort to generate a comprehensive B cell epitope map of RTA and define, at the structural level, interactions between antibodies and ricin that are important in toxin-neutralization.
Materials and Methods

Identification of V H Hs A9 and V8A7
A V H H phage-displayed library (referred to as 'Clash') was constructed from two alpacas immunized with a novel ricin toxoid consisting of RiVax reconstituted with native RTB (D. Vance, J. Trembley, C. Shoemaker, and N. Mantis, manuscript in preparation). The Clash library was constructed essentially as described (Vance et al., 2013) . V H Hs A9 and V8A7 were identified from two separate screens: A9 was identified in a panning directly on plate bound RTA, while V8A7 was identified in a screen in which ricin was captured by the anti-RTB mAb SylH3 (D. Vance, C. Shoemaker, N. Mantis, manuscript in preparation). Both screens consisted of a low (round 1) and high (round 2) stringency panning in which target antigen was present at 10 μg/ml or 1 μg/ml, respectively ). A9 and V8A7 V H Hs were expressed in E. coli Rosetta-gami 2 (DE3)pLacI (EMD Millipore, Billerica, MA) as fusion proteins with an N-terminal thioredoxin tag, a linker containing a hexa-his purification tag, and a C-terminal epitopic E-tag (GAPVPYPDPLEPR).
ELISA
For competition ELISAs, NUNC microtiter plates were coated with competitor capture mAbs (1 μg/ml in PBS) overnight at 4°C and then blocked for 2 h with 2% goat serum in 0.1% PBS-T. Biotinylated-ricin, at a predetermined EC 90 value for each individual mAb, was mixed with 2-fold dilutions of V H H antibodies, and then added to the mAb coated plate. Bound biotinylated-ricin was detected with streptavidin-HRP and developed with SureBlue TMB substrate (KPL). After quenching with 1 M phosphoric acid, absorbance at 450 nm was determined using a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA).
Vero cell cytotoxicity assays
Relative IC 50 s were determined in a Vero cell cytotoxicity assay (Wahome and Mantis, 2013) . Vero cells were detached from culture dishes with trypsin, adjusted to~5 ×10 4 cells per ml and seeded (100 μl/well) into white 96-well plates (Corning Life Sciences, Corning, NY) and allowed to adhere overnight. The cells were then treated with ricin (0.01 μg/ml; 154 pM), ricin:V H H mixtures, or medium alone (negative control) for 2 h at 37°C. The cells were washed and then incubated for 48 h at 37°C, after which time cell viability was assessed using CellTiter-GLO (Promega, Madison, WI). All treatments were performed in triplicate. Relative IC 50 s were determined following published guidelines in which 100% viability was derived from cells that were treated with medium only, while 0% viability was defined as the average value obtained from ricintreated cells (Sebaugh, 2011) . Reported relative IC 50 values for each V H H were derived from at three independent toxin-neutralizing assays (each done in triplicate).
Cloning, expression and purification of V H Hs
For the purpose of X-ray crystallography, the PCR amplicons of A9 (residues 1-137), V8A7 (1-136), and A9 with Gly-59 deleted (referred to as A9Δ59) were subcloned into the N-terminally decahistidine SUMO tagged pSUMO expression vector and RTA (residues 1-268) was subcloned into the N-terminally deca-histidine tagged MCSG7 expression vector using a standard ligase independent cloning protocol. The VHHs and RTA were expressed in and purified from E. coli strain BL21(DE3)-pRARE, as described previously (Rudolph et al., 2014) . In order to generate A9-RTA protein complex for crystallization, purified RTA was mixed in a 1:1 stoichiometry with A9 and put over a Superdex 75 10/300 gel filtration column pre-equilibrated in 20 mM Tris pH 7.5 and 150 mM NaCl to isolate the complex from monomeric RTA or A9.
Crystallization and data collection
The A9-RTA and A9 crystals were grown by sitting drop vapor diffusion at 20°C using a protein to reservoir volume ratio of 1:1 with total drop volumes of 0.4 μl. Crystals of the RTA-A9 complex were produced using crystallization buffer containing 100 mM Tris (pH 8.5) and 2 M ammonium dihydrogen phosphate. Crystals of the A9 were grown against crystallization buffer containing 100 mM Bicine (pH 9.0) and 2.4 M ammonium sulfate. All crystals were flash frozen in liquid nitrogen after a short soak in the appropriate crystallization buffers supplemented with 20-25% ethylene glycol. Data were collected at the 24-ID-E beamline at the Advanced Photon Source, Argonne National Labs. All data was indexed, merged, and scaled using HKL2000 (Otwinowski and Minor, 1997 ) then converted to structure factors using CCP4 (Winn et al., 2011) .
Structure determination and refinement
The structures of A9-RTA and A9 were solved by molecular replacement using the program Phaser (McCoy et al., 2007) . Molecular replacement calculations were performed using the coordinates of the RTA as a search model for RTA (PDB code 1RTC) for the A9-RTA complex. The V H H coordinates used as a search model for the A9 structure was D10 (PDB code 4LGR). The resulting phase information from molecular replacement was used to autobuild the polypeptide chain for A9 using the program ARP (Morris et al., 2003) , which was able to trace most residues. This A9 structure was used as a search model for the A9-RTA complex structure. Further manual model building was performed with COOT (Emsley et al., 2010) combined with structural refinement employing the PHENIX package (Adams et al., 2010 ). Twinned refinement was performed for the A9-RTA complex using the twin operator h,-h-k,-l with a twinning fraction of 0.5. During refinement a cross-validation test set was created from a random 5% of the reflections. Data collection and refinement statistics are listed in Table S1 . Molecular graphics were prepared using PyMOL (Schrodinger; DeLano Scientific LLC, Palo Alto, CA).
Accession numbers
The structures generated in this study were deposited in the Protein Data Bank (PDB; http://www.rcsb.org/pdb/) (Berman et al., 2000) under accession numbers 6CWG for A9-RTA and 6CWK for A9, as described in Tables I and S1 .
Epitope mapping by HX-MS
We employed HX-MS to localize the V H H binding sites on RTA, as described (Bazzoli et al., 2017) . For reasons of safety, a recombinant, attenuated variant of RTA known as RiVax was used for mapping studies. RiVax differs from RTA at two positions: V76M and Y80A. RTA-V H H complexes were formed at pH = 7.4 in 10 mM sodium phosphate buffer using a 1:2 molar ratio of RTA:V H H with an RTA concentration of 20 μM. RTA and RTA in complex with each V H H were labeled with a 10-fold excess of a D 2 O solution of the same buffer at pD 7.4 corrected for the deuterium isotope effect (Glasoe and Long, 1960) . Following standard procedures for quench, pepsin digestion, and LC-MS, the regions of RTA where the extent of HX was significantly slower (protection) or faster (deprotection) in the presence of V H H were identified using k-means clustering and significance testing based on time-averaged differential HX measurements HX ∆ . Unlike in the previous work, the results here were filtered for solvent accessibility of the RTA residues (R. Toth IV, D. Weis, manuscript in preparation). The strength of protection HX 0 (∆ < ) or deprotection HX 0 (∆ > ) was assigned using k-means clustering. The regions that were assigned as strongly protected were used to define epitopes. The reference RTA peptide map generated following pepsin digestion is shown in Table S2 .
Computational loop modeling
The A9 and A9Δ59 structures were modeled in complex with RTA using a combination of Rosetta loop modeling and custom analysis in PyRosetta (Chaudhury et al., 2010) . To model A9 (for benchmarking), we used PyRosetta's native set_phi and set_psi methods to set all dihedrals in the loop to 180°to cut the CDR2 loop open. Next, we randomly adjusted ϕ/ψ for a residue in a shear move (by up to a maximum of 150°), accepting/rejecting the move based on Monte Carlo Metropolis criterion that includes an energy term for penalizing chain breaks in the loop. After 300 cycles of ϕ/ψ randomization, we performed cyclic coordinate descent (CCD) loop closure (Canutescu and Dunbrack, 2003) to close any breaks in the loop if present. The approach above was repeated 10 000 times to yield 10 000 output structures. All atoms outside the CDR2 loop remained fixed throughout this procedure. To model A9Δ59, we started from the A9 structure and randomly deleted one of the five glycine residues in the CDR2 loop. The ϕ/ψ angles were randomized as in the A9 case, and CCD was applied to all models. The energy of each model (in complex with RTA) was determined in Rosetta using the 'REF15' fullatom energy function. We also used the bouunbou_nrg application to evaluate the interaction energy, including complete minimization of the complex and the unbound component proteins.
Clustering loop models
The resulting sets of 10 000 models for each of A9 and A9Δ59 were individually clustered using our variant of the DBSCAN (Sander et al., 1998) algorithm (Grid-Graph DBSCAN). The distance metric for clustering was based on the internal dihedral angles of the loop, and is similar to that described in our previous clustering of antibody CDRs (North et al., 2011) :
Previously we chose the metric as the sum of all d for each pair of corresponding residues in each loop; for this study, however, we instead chose the maximum value of d for the comparison of each residue:
This newer metric penalizes conformations which are far away at even one residue, thus clustering together only loops that resemble each other very closely throughout. After calculating D between each pair of loops in our set, we clustered the resulting pairwise matrix using the DBSCAN algorithm. To determine the best parameter combination of DBSCAN, we first scanned the parameters by changing ε and MinPts. Subsequently, we calculated overlap between clusters at each pair of chosen parameters by calculating the Simpson score between the pair of clusters:
Clusters with a Simpson similarity score of at least 0.10 were merged by taking the union between the two clusters. Any clusters with Simpson score less than 0.1 were discarded as noise.
Results
A9 was isolated from a V H H phage displayed library derived from two alpacas vaccinated with ricin toxoid consisting of RiVax in association with native RTB (D. Vance, J. Trembley, C. Shoemaker, and N. Mantis, manuscript in preparation). Although A9 had relatively weak toxin-neutralizing activity (IC 50~7 50 nM), it was considered an antibody of interest because of its somewhat unusual competition profile against a panel of mAbs representing the four immunodominant clusters in RTA (Fig. 1) . A9 when bound to ricin strongly inhibited ricin capture by mAbs PB10 and IB2, suggesting A9's binding site straddles epitope clusters I and III. Cluster I has been extensively studied at the structural level and involves various degrees of contact with β-strand h (residues 112-118), α-helix B (residues 97-107), and the C-terminal region of α-helix D (residues 154-156) (Rudolph et al., 2014 (Rudolph et al., , 2016 Toth et al., 2017; Vance et al., 2017) . Cluster III is defined as contacts with α-helix C (residues 123-130) and α-helix G (residues 207-217) (Toth et al., 2017; Vance et al., 2017) .
To define A9's epitope at the atomic level, we solved the X-ray crystal structure of A9 alone and A9 in complex with RTA at 1.3 Å and 2.6 Å resolution, respectively (Table I; Fig. 2 ; Table S1 ). A9 assumed a classical immunoglobulin fold consisting of nine β-strands arranged in two β-sheets with CDRs 1-3 on one face of the molecule. A9 has two intramolecular disulfide bridges: one between residues Cys-22 and Cys-98 linking CDR1 and CDR3, and a second non-canonical bond between residues Cys-53 and Cys-105 linking CDR2 and CDR3. The tertiary structures of A9 in the free and RTA-bound forms were essentially identical, as evidenced by an overall RMSD of 0.9 Å (Fig. S2) . One notable deviation between these two structures occurred within the CDR2 region at Gly-57 where the Ca atoms were 3.3 Å apart.
As predicted from the competition ELISA with mAb PB10, A9 makes extensive contact with RTA β-strand h (Table II; Fig. 3) . Specifically, A9's CDR3 formed eight intermolecular hydrogen bonds with β-strand h, burying a total of 732 Å 2 of solvent-exposed surface area. The three main chain hydrogen bonds between CDR3's β-strand (residues 105-107) and RTA's β-strand h (residues 115-117) result in the formation of a seventh β-strand within RTA's centrally located β-sheet (Fig. 2) . In this respect A9 resembles two previously described V H Hs, G12 and A7 (Rudolph et al., 2014 (Rudolph et al., , 2016 ). A9's CDR3 also formed a single hydrogen bond with α-helix D mediated by Tyr104 (A9) and Tyr 154 (RTA), burying an additional 90 Å 2 with RTA (Table II ; Fig. 3 ).
CDR1 and CDR2 also make consequential interactions with RTA. With respect to CDR1, Asp-28 forms a salt bridge with Arg-125 from RTA's α-helix C in one of the A9-RTA dimers within the asymmetric unit, thereby explaining competition with IB2 by ELISA. CDR1 binding to α-helix C also buries 138 Å 2 (Table II ; Fig. 4 ). The crystal structure of A9 bound to RTA revealed that CDR2 contacts RTA's α-helix B (Fig. 3) . This interaction is noteworthy because mAbs and V H Hs that bind α-helix B typically possess potent toxinneutralizing activity (Lebeda and Olson, 1999; Rudolph et al., 2014 Rudolph et al., , 2016 ) (Rudolph et al., 2014) . Therefore, we speculate that A9's engagement with α-helix B contributes to the antibody's toxin-neutralizing activity.
An important role for A9's CDR2 in toxin-neutralizing activity was reinforced by the discovery of a second RTA-specific V H H, V8A7. V8A7 and A9 differ from each other at only two positions (Fig. 5A) . At position 7, A9 has a Ser, while V8A7 has a Thr. This difference is likely the result of degenerate primer misalignment during V H H phage display library construction (C. Shoemaker, personal communication). The second disparity is within CDR2: A9 has five consecutive Gly residues (corresponding to positions 55-59), whereas V8A7 has four. Thus, V8A7's CDR2 is one residue shorter than A9. The presumed alpaca germline V H gene of these two V H Hs is IGHV3-3*01 (IMGT ® , the international ImMunoGeneTics information system ® ). In CDR2, IGHV3-3*01 has two consecutive Gly residues followed by a Ser residue. DNA and protein sequence alignments of A9 and V8A7 with IGHV3-3*01 suggests that V8A7 is a late evolutionary intermediate on the path towards A9 (Fig. S3) . Indeed, discounting primer degeneracy differences in the N-terminal region, A9 and V8A7 differ in only two nucleotides, both of which are silent.
Despite being almost identical to A9, V8A7 was essentially devoid of toxin-neutralizing activity (Fig. 5B) . Moreover, V8A7's binding affinity (K D ) was 50-fold lower for ricin holotoxin than A9's (3.95 nM versus 0.08 nM). While efforts to solve the X-ray crystal structure of V8A7 bound to RTA were not successful, HX-MS analysis indicated that V8A7 and A9 had essentially identical binding (protection) sites on RTA, even though the relative strength of protection was lower in the case of V8A7 (Table III; Fig. 6 ; Fig. S4 ). Thus, epitope specificity per se is not likely to explain why V8A7 and A9 have such different binding affinities and toxinneutralizing activities.
Nonetheless, these results implicate the difference of a single Gly residue in CDR2 as accounting for the functional disparities between V8A7 and A9. To examine this hypothesis more rigorously, we generated de novo recombinant V H H A9, a variant lacking Gly residue 59 (A9Δ59), and V8A7. Binding studies and toxinneutralizing assays with these three V H Hs confirmed that the removal of a single glycine residue from A9's CDR2 significantly reduced binding affinity for RTA (~10-fold weaker; 1.76 nM versus 0.102 nM) and eliminated toxin-neutralizing activity (Table IV; Fig.  5; Fig. S5 ). In an effort to interpret at the molecular level why the omission of a single Gly residue within CDR2 has such a profound effect on binding affinity, we studied A9Δ59 using computational loop modeling. CDR H2 length 11 does not cluster into any canonical conformations from the PDB (North et al., 2011) (Fig. S6) , nor does the sequences of A9 CDR2 with the glycine deletion (Table S3) . Therefore, we could not rely on traditional homology modeling or CDR grafting techniques to investigate the effect of the Gly59 deletion on CDR2 structure and RTA-A9 binding. Instead, we modeled the A9Δ59 using a combination of Monte Carlo sampling of the glycine backbone dihedrals ϕ and ψ, and the Cyclic Coordinate Descent (CCD) (Canutescu and Dunbrack, 2003) loop closure algorithm implemented in the Rosetta macromolecular modeling suite (Leaver-Fay et al., 2011), as described in the Materials and Methods.
For each of A9 and A9Δ59, we randomized and re-built the CDR2 loop 10 000 times and then clustered the resulting loops, as described in the Materials and Methods. This step is an essential complement to energy-based ranking of the resulting models, since it points to which families of loops are commonly observed among our models, versus those that are noisy predictions (poorly sampled). The distance metric for this clustering was a function of the largest dihedral angle difference between corresponding ϕ and ψ values in each of two loops (North et al., 2011) . To select the best model, we identified the cluster with the lowest average energy (Fig. 7) , then took the model with the lowest energy from this cluster. We further noted that the A9 crystal structure was grouped with the lowestenergy cluster of our A9 models, indicating that our loop modeling approach had successfully recapitulated this structure (Fig. 8) .
Both the bound and unbound crystal structures of the A9 loop include an intra-CDR2 hydrogen bond network that surrounds Cys53 (Fig. 9A,B ). Cys53 forms a disulfide bond with Cys105 in CDR3, preceding formation of the interacting anti-parallel β-strand pair between CDR3 and β-strand h. The same hydrogen bond network was recapitulated in the modeled structures of A9 (Fig. 9C) , but it was lost in the models of A9Δ59 (Fig. 9D) . We anticipate that Fig. 4 Comparison of the interactions between A9, G12, and A7 with RTA's α-helix C. Zoom-in of the interaction between the CDR1 of (A) A9, (B) G12, and (C) A7 with RTA's α-helix C. RTA (green) and each CDR1 (blue) are drawn as Cα-traces. Side chains are drawn as sticks and color coordinated to the main chain color. The salt bridge between A9 Asp28 and Arg125 is represented as a red dashed line. loss of this network would reduce the stability of CDR2 in A9Δ59, potentially disrupting Cys53 and making the loop more flexible. The loss of stability in CDR2 may also lead to increased conformational entropy in this loop, which must be accounted for upon RTA binding. Based on our loop modeling results, then, we speculate that the difference in binding affinity between A9 and A9Δ59 derives not from the direct contacts of CDR2 with RTA per se, but rather from A9Δ59's increased flexibility.
Discussion
The current study describes the molecular interactions between a single-domain camelid antibody, A9, and RTA, the enzymatic Binding kinetics with de novo synthesized V H Hs were determined by SPR, as described in Materials and Methods. Fig. 7 Energetic comparison of conformational cluster from loop modeling. Box plots are shown for each cluster of output model for (A) A9 and (B) A9D59. Each cluster is shown along the x-axis, for both groups. The energies for A9 and A9D59 are not directly comparable to one another, because there are a different number of atoms in the two systems. For A9, cluster 2 had the lowest average energy, and also included the crystallographic loop conformation. For A9D59, cluster 11 had the lowest average energy and was therefore selected as our predicted conformation, despite the fact that it did not include the individual model with the lowest energy. The final predicted model was taken to be the lowest-energy structure from the cluster with the lowest average energy.
subunit of ricin toxin. The work advances our ongoing effort to generate a comprehensive B cell epitope map of ricin and define, at the structural level, residues and secondary structural elements important for eliciting toxin-neutralization. A9 was originally deemed to be an 'antibody of interest' because of its somewhat unusual profile in a competition ELISA with mAbs representing the four immunodominant clusters (I-IV) on RTA. The results had suggested that A9 contacts regions associated with clusters I and III. This observation was borne out at the structural level in that A9 contacts the core secondary structural elements of cluster I, namely β-strand h, α-helix B and α-helix D, as well as a core element of cluster III, namely α-helix C.
In terms of its interactions with RTA, A9 shares structural similarities with previously described cluster I V H Hs, namely G12 and A7 (Table II) (Rudolph et al., 2014 (Rudolph et al., , 2016 . A comparison of these RTAantibody complexes (A9, G12 and A7) highlights subtle structural differences that may explain their differential toxin-neutralizing activities: G12 (IC 50~3 00 nM) is more potent than A9 (IC 50 of~750 mM), which is more potent than the non-neutralizing A7 (Table II) .
Although the overall structures of A9 and G12 bound to RTA are very similar (RMSD of 1.9 Å for all Cα atoms), there are pivotal differences in the nature of the β-sheet interactions between their respective CDR3 elements and RTA's β-strand h. As a rule, CDR3 configurations of V H Hs are heavily influenced by hydrophobic interactions with framework region (FR) residues that ultimately tether CDR3 residues to the surface of the antibody. The primary difference between G12 and A9 with respect to their β-sheet interactions with RTA is due to slight deviations in the position of one of the FR-CDR3 hydrophobic interactions that, when combined with different CDR3 lengths, alters the relative binding of each antibody to RTA. G12's β-sheet interaction with RTA's β-strand h consists of five main chain hydrogen bonds between the CDR3 β-strand (residues 103-107) and RTA's β-strand h (residues 113-117) (Fig. 7) . By comparison, RTA-A9's β-sheet interaction consists of only three main chain hydrogen bonds (residues 105-107) with RTA's β-strand h (residues 115-117) (Fig. 10) . The truncated CDR3 connection to β-strand h in A9 is the result of the hydrophobic interaction between FR Phe47 and Tyr61 with CDR3 residue Tyr110 in A9. This interaction effectively pulls residues 108 and 109 away from β-strand h, precluding the possibility of hydrogen bonding between these CDR3 residues with β-strand h (Fig. 10) . The analogous hydrophobic association between Phe47 and Tyr61 with Tyr111 in G12 also moved (yellow) is superposed with the crystal structure of A9 (cyan). The conformations are in excellent agreement, demonstrating the utility of this approach for modeling this CDR2 loop. (B) A9Δ59 predicted CDR2 loop conformations from the lowest-energy cluster (orange) is superposed with the crystal structure of A9 (cyan). The shorter loop does not allow A9Δ59 to adopt the same loop conformation that is observed in the A9 crystal structure. Fig. 9 Disruption of the hydrogen bond network in CDR2. (A) The CDR2 conformation from the crystal structure of A9 bound to RTA. A hydrogen bond network (yellow dashes) stabilizes this loop, and in particular Cys53 (which additionally forms a disulfide bond with Cys105 on CDR3). (B) The CDR2 conformation from the crystal structure of A9 alone shows a very similar hydrogen bond network, indicating that this loop is pre-ordered for RTA binding. (C) The CDR2 conformation from our loop modeling of A9 also includes a similar hydrogen bond network. (D) This hydrogen bond network is disrupted in the loop modeled structures of A9Δ59. In all cases, hydrogen bonds were defined using the HBPlus software (McDonald and Thornton, 1994) .
residues 109 and 110 away from β-strand h (Fig. 10) . However, because G12's CDR3 sequence is two residues longer (Fig. 10 ), Thr106 and Gly107 are still in a position to form a β-sheet interaction with β-strand h. As a result, G12 interacts with β-strand h more than A9, as demonstrated by G12's greater BSA (870 Å 2 ), compared to A9 (732 Å 2 ). While α-helix B is the de facto 'neutralizing hot spot' within RTA's cluster I, contact with RTA's β-strand h is also associated with toxin neutralization, albeit to a much lesser degree. Consequently, the attenuated interaction of A9 with β-strand h likely contributes to the relatively weaker neutralizing capacity of A9 relative to G12.
The truncated β-sheet interaction between A9 and RTA also led to the entire A9 subunit rotating~14.5°away from the unattached, N-terminal segment of β-strand h, as compared to the position of G12 bound to RTA (Fig. 11) . Interestingly, the relative rotation of A9 bound to RTA positioned its CDR2 closer to RTA's α-helix B compared to G12's CDR2 position (Fig. 11 ). A9's slightly longer CDR2 (Fig. 10C ) also provided further reach resulting in two CDR2 residues in A9, Gly-55 and Gly-57, contacting RTA's α-helix B. A9 only made contact with the N-terminal portion of α-helix B (residues 97 and 101), generating a small interface with RTA that buried a total surface area of 82 Å 2 . The limited contact between A9 and RTA's α-helix B likely results in much of A9's weak toxinneutralizing activity (IC 50 of~750 nM), as other antibodies that bind α-helix B extensively tend to have stronger toxin-neutralizing activity (Rudolph et al., 2014 (Rudolph et al., , 2016 As noted in the Results, deletion of a residue Gly-59 abolished A9's toxin-neutralizing activity, which we originally had attributed to a shortening of CDR2. However, molecular modeling indicates A9Δ59 has increased flexibility relative to A9 that lowers its propensity to form stable interactions with α-helix B. V H H A7, which lacks toxin-neutralizing activity, forms a truncated β-sheet interaction between CDR3 (residues 103-104) and RTAs β-strand h (residues 116 and 117) that is similar to A9. Instead of hydrophobic interactions between FR and CDR3 residues abbreviating the β-sheet interaction as seen in A9, the CDR3 in A7 possessed a Pro residue at position 106, which lacks the amide hydrogen required for β-sheet formation, while also generating a bend within the main chain that causes the ensuing C-terminal residues within the CDR3 to project away from RTA, thereby lessening contact with β-strand h. A7's Met105 also runs away from RTA's β-strand h because of hydrophobic interactions between its side chain and several hydrophobic FR residues (Tyr102 and Tyr116) within A7. Those same residues also averted hydrogen bonding between Met105 and RTA's β-strand h (Fig. S7) . The attenuated β-sheet in A7 induced an equivalent position of A7 with respect to RTA as seen in the RTA-A9 complex resulting in very similar structures between RTA-A7 and RTA-A9 (RMSD of 0.9 Å for all Cα atoms) (Fig. 12) . Despite the strong structural resemblance between A7 and A9 bound to RTA where both antibodies make very similar contacts to β-strand h and α-helix D, only A9 contacted α-helix B due to A9's longer CDR2 (10 residues in A9 compared to 8 residues in A7) which furnished the greater length required for the interaction between its CDR2 and α-helix B (Fig. 10) . Since A9 and A7 Fig. 10 Key residues influencing CDR3 interaction with RTA. The Cα-traces of (A) V H H A9 and (B) V H H G12. The V H Hs are colored cyan with their CDR3 elements colored red. Key residues forming hydrophobic interactions are drawn as sticks and color coordinated to their respective main chain color. The disulfide bond between residues Cys53-Cys105 in A9 is shown in stick representation and colored magenta. (C) Sequence alignment of A9, G12 and A7. CDR1, 2 and 3 are highlighted with blue, yellow, and red, respectively. Cysteines forming the disulfide bond between FR residues are colored brown. Cysteines forming the disulfide between CDR2 and CDR3 residues in A9 residues are highlighted magenta. Black asterisks below the sequence denote sequence identity. Fig. 11 Comparison of RTA-A9 and RTA-G12 interfaces. (A) The superpositioned Cα-traces of RTA in complex with V H H A9 (green-cyan, respectively) and V H H G12 (gray-gray, respectively). The cyan arrow illustrates direction of the~14.5°rotation of A9 from the center of the RTA-VHH interface relative to G12. The inset illustrates the truncated interaction between A9's CDR3 and RTA's β-strand h compared to the RTA-G12 interaction. The two additional main-chain hydrogen bonds that at the RTA-G12 interface, absent in the RTA-A9 interface, are drawn as red dashes. (B) A close-up of the superpositioned Cα-traces of RTA-A9 (green-cyan, respectively) and RTA-G12 (gray-gray, respectively). The CDR2 and CDR3 elements in A9 are colored yellow and red in A9, respectively, and graygray in G12. RTA secondary structural element α-helix B (Residues 97-107) is labeled highlighting the proximity of A9's CDR2 to this secondary structural element in RTA.
uniformly interact with β-strand h and α-helix D yet only A9 has toxin-neutralizing activity, A9's exclusive interaction with α-helix B further highlights antibody interaction with this region of RTA evidently diminishes ricin toxin function.
Another pivotal difference across A9, A7, and G12 V H Hs is that A9's CDR1 makes significant contact with RTA's α-helix C, forming a salt-bridge between CDR1 residue Asp-28 with Arg-125 in α-helix C while also burying 138 Å 2 . A7 and G12 make very little contact with α-helix C, burying only 30 and 12 Å 2 , respectively, without establishing any salt bridges (Table II) . G12 does not significantly contact α-helix C because its CDR1 is rotated away from α-helix C compared to A9's CDR1 due to the~14.5°relative rotation of G12 to A9 when each are bound to RTA which ultimately positions G12's CDR1 too far away from α-helix C to form any sizable interaction (Fig. 4) . A7 does not appreciably contact α-helix C despite the strong structural resemblance between A7 and A9 bound to RTA, as two of the A9 CDR1 residues that bind α-helix C, Arg-27 and Asp-28, in A7 are instead Gly-27 and Ser-28 which are incapable of reaching α-helix C. The different interaction between these antibodies with RTA's α-helix C demonstrates why we observe competition between A9 and IB2 in our ELISA assay and not G12 and A7. Although the interface between A9 and α-helix C does not completely occlude α-helix C, the interaction provides ample steric obstruction that could conceivably occlude IB2 from accessing this region of RTA.
Although A9, and not G12 or A7, engaged α-helix C, we attribute the primary difference in toxin-neutralizing activity among these antibodies as being due to the stable association with α-helix B. At the structural level, two Gly residues (55 and 57) within a stretch of five Gly-residues in CDR2 make contact with α-helix B, burying a total of 82 Å 2 . Removal of one of the five consecutive Gly residues in A9Δ59's CDR2 resulted in a decrease in antibody binding affinity of~20-fold, as well as a loss of toxin-neutralizing activity; we attribute this to loss of an intra-CDR hydrogen bond network in the shorter CDR2, which in turn leads to greater conformational entropy of the unbound antibody. The important functional effect stemming from a subtle change in CDR2 highlights the formidable impact that CDR2 has on A9's binding affinity and toxin-neutralizing activity.
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